The predictive value ofKRAS, NRAS, BRAF, PIK3CAand PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

The predictive value ofKRAS, NRAS, BRAF, PIK3CAand PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis

Published:2014-03-25 Issue:7 Volume:53 Page:852-864
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Therkildsen Christina,Bergmann Troels K.,Henrichsen-Schnack Tine,Ladelund Steen,Nilbert Mef

Publisher

Informa UK Limited

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.3109/0284186X.2014.895036

Reference36 articles.

1. Cancer statistics, 2013

2. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

3. EGFR Antagonists in Cancer Treatment

4. Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

5. Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

Cited by 325 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. miR-29a expression negatively correlates with Bcl-2 levels in colorectal cancer and is correlated with better prognosis;Pathology - Research and Practice;2024-10

2. The RAS/BRAF genes status in patients with colorectal cancer (review);Koloproktologia;2024-09-21

3. Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics;Protein Science;2024-09-14

4. New Perspectives in Colorectal Cancers Treatment, the Role of MicroRNAs;Current Drug Targets;2024-09

5. Real-world cost-effectiveness of panel-based genomic testing to inform therapeutic decisions for metastatic colorectal cancer;Journal of Cancer Policy;2024-09